The content on this site is intended for healthcare professionals only
Dr Sophie Postel-Vinay speaks to ecancer about the PIPSeN trial. Initially, she explains the background of this trial.
PIPSeN is a randomised, double-blind phase II study that evaluated the PARPi olaparib as maintenance treatment in patients with platinum-sensitive advanced NSCLC.
Dr Postel-Vinay then discusses the methodology and key results of this trial. PIPSeN was terminated early with only 50% of the pre-planned patient population available for analysis, thus being statistically underpowered.
She concludes that although well-tolerated, olaparib maintenance did not improve median PFS nor median OS in this sample of patients with platinum-sensitive NSCLC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Pegargiminase-pemetrexed-platinum triplet therapy prolongs survival in non-epithelioid pleural mesothelioma
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
